JP2008504551A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504551A5
JP2008504551A5 JP2007518700A JP2007518700A JP2008504551A5 JP 2008504551 A5 JP2008504551 A5 JP 2008504551A5 JP 2007518700 A JP2007518700 A JP 2007518700A JP 2007518700 A JP2007518700 A JP 2007518700A JP 2008504551 A5 JP2008504551 A5 JP 2008504551A5
Authority
JP
Japan
Prior art keywords
gsk
level
disease
alzheimer
inactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007518700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504551A (ja
Filing date
Publication date
Priority claimed from GBGB0414894.6A external-priority patent/GB0414894D0/en
Application filed filed Critical
Publication of JP2008504551A publication Critical patent/JP2008504551A/ja
Publication of JP2008504551A5 publication Critical patent/JP2008504551A5/ja
Withdrawn legal-status Critical Current

Links

JP2007518700A 2004-07-02 2005-07-01 アルツハイマー病のバイオマーカー Withdrawn JP2008504551A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0414894.6A GB0414894D0 (en) 2004-07-02 2004-07-02 Biomarkers of alzheimer's disease
PCT/GB2005/002592 WO2006003414A2 (en) 2004-07-02 2005-07-01 Biomarkers of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2008504551A JP2008504551A (ja) 2008-02-14
JP2008504551A5 true JP2008504551A5 (enExample) 2008-08-21

Family

ID=32843494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518700A Withdrawn JP2008504551A (ja) 2004-07-02 2005-07-01 アルツハイマー病のバイオマーカー

Country Status (9)

Country Link
US (1) US20080076140A1 (enExample)
EP (1) EP1763674A2 (enExample)
JP (1) JP2008504551A (enExample)
CN (1) CN101010589A (enExample)
AU (1) AU2005258926A1 (enExample)
BR (1) BRPI0512948A (enExample)
CA (1) CA2571692A1 (enExample)
GB (1) GB0414894D0 (enExample)
WO (1) WO2006003414A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138408A1 (en) 2006-05-25 2007-12-06 Ge Healthcare Limited 11c/18 f-labeled inhibitors of glycogen synthase kinase-3
WO2009074331A2 (en) * 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
EP2279420B1 (en) 2008-03-21 2014-01-29 Manuela G. Neuman METHODS FOR THE DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE VERSUS FRONTOTEMPORAL DEMENTIA, COMPRISING FAS-L, TNF-alpha AND ccCK-18 AS BIOMARKERS
US20100151457A1 (en) * 2008-12-17 2010-06-17 National Tsing Hua University Detection of Unhealthy Cell and Uses Thereof
US20120040361A1 (en) * 2010-07-22 2012-02-16 National Tsing Hua University Methods and compositions for detection of lethal system and uses thereof
CN104237526B (zh) * 2013-06-18 2016-08-17 磁量生技股份有限公司 一种检测阿兹海默症罹患风险的系统
US20170102398A1 (en) * 2014-03-05 2017-04-13 Humanetics Corporation Predicting and reducing cognitive decline based on gsk-3 levels
CN104698188A (zh) * 2015-03-04 2015-06-10 华中科技大学 检测人血小板GSK-3β蛋白活性的斑点印迹方法
CN111323597A (zh) * 2018-12-14 2020-06-23 陈志成 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005240669A1 (en) * 2004-05-07 2005-11-17 Garvan Institute Of Medical Research Detecting disease association with aberrant glycogen synthase kinase 3-beta expression

Similar Documents

Publication Publication Date Title
Dong et al. Sputum and salivary protein biomarkers and point-of-care biosensors for the management of COPD
Dharnidharka et al. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis
Fan et al. Diagnosing sepsis–The role of laboratory medicine
Liangos et al. Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure
Judd et al. Update of fecal markers of inflammation in inflammatory bowel disease
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
Palone et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission
JP2012509477A5 (enExample)
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
NO20083820L (no) Deteksjon av kreft ved forhoyede nivaer av BCL-2
JP2006521565A5 (enExample)
JP2016503301A5 (enExample)
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
JP2008537474A5 (enExample)
JP2013504766A5 (enExample)
Levy et al. Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients—a single‐center retrospective cohort study
JP2008504551A5 (enExample)
JP2018536170A5 (enExample)
Jung et al. Association of waist circumference, traditional cardiovascular risk factors, and stromal‐derived factor‐1 in adolescents
JP2014505254A5 (enExample)
WO2005085292A3 (fr) Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
JP2008538812A5 (enExample)
RU2008103988A (ru) Способ диагностики рассеяного склероза
CN107589260A (zh) 尿液中mmp-7作为肾脏纤维化和慢性肾脏病的生物标志物的用途
JP2012533066A5 (enExample)